Braveheart's HCM Drug Holds Obstruction Gains at 52 Weeks With No Serious Events
BRVE is trading near its 52-week low of $16.7 (9.6% above the low).
Summary
Braveheart reported 52-week data from a 42-patient open-label extension of HRS/BHB-1893 in hypertrophic cardiomyopathy: 79% of patients had a Valsalva LVOT gradient below 30 mmHg, peak oxygen uptake rose 2.7 mL/kg/min and KCCQ-CSS symptom scores improved 17.3 points from extension baseline. No on-treatment severe or serious adverse events were reported. The results support durability and tolerability, but the extension is open-label and uncontrolled, so they don't establish efficacy on their own. This follows the September 8-K where the company reported $122.8M in cash ($527.3M pro forma for the IPO) and started the Phase 3 LIONHEART program. The next real test is the planned fixed-dose Phase 2b oHCM study, which would show whether the dose-simplification effect holds in a controlled trial.
At the time of this announcement, BRVE was trading at $18.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $16.70 to $32.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.